Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"LTS - Lohmann Therapie Systeme","sponsor":"Livzon Pharmaceutical Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LTS and LIVZON Enter into License and Collaboration Agreement to Develop and Commercialize Asenapine TTS","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharmaceuticals Announces USFDA Final Approval for Asenapine Sublingual Tablets, 5 mg and 10 mg","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results from Pivotal, Phase 3 Trial for SECUADO\u00ae (asenapine) Published in Journal of Clinical Psychiatry","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Asenapine

    Menu

    Asenapine

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Noven Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Results from Pivotal, Phase 3 Trial for SECUADO® (asenapine) Published in Journal of Clinical Psychiatry

              Details:

              SECUADO achieved the primary endpoint, demonstrating statistically significant improvement in Positive and Negative Syndrome Scale (PANSS) total score change from baseline to Week 6 compared to placebo.

              Lead Product(s): Asenapine Maleate

              Therapeutic Area: Psychiatry/Psychology Product Name: Secuado

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 15, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Alembic Pharmaceuticals Limited

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Alembic Pharmaceuticals Announces USFDA Final Approval for Asenapine Sublingual Tablets, 5 mg and 10 mg

              Details:

              The approved ANDA is therapeutically equivalent to the reference listed drug product, Saphris Sublingual Tablets, 5 mg and 10 mg, of Allergan. Asenapine is an atypical antipsychotic indicated for bipolar I disorder as adjunctive treatment to lithium or valproate in adults.

              Lead Product(s): Asenapine Maleate

              Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 11, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              LTS - Lohmann Therapie Systeme

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              LTS and LIVZON Enter into License and Collaboration Agreement to Develop and Commercialize Asenapine TTS

              Details:

              LTS grants to LIVZON and its Affiliates an exclusive royalty-bearing, sublicensable right and license to jointly develop with LTS the Asenapine TTS and commercialize the Asenapine TTS for the treatment of schizophrenia in China (including Hong Kong and Macau).

              Lead Product(s): Asenapine Maleate

              Therapeutic Area: Psychiatry/Psychology Product Name: Asenapine TTS

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Livzon Pharmaceutical Group

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement July 06, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY